Clinical Trial Update: Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History [Phase 3]

View source ↗

Summary

Phase 3 trial update on benralizumab for moderate to very severe COPD with a history of exacerbations; results completed and posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-06-26